Chemical Biological Medical Systems – Therapeutics consists of the following components:
- Improved Nerve Agent Treatment System (INATS): This system is an enhanced treatment regimen to counter the effects of nerve agent poisoning. The new oxime component of INATS will replace 2-pyridine aldoxime methyl chloride in the Antidote Treatment Nerve Agent Autoinjector. In addition, U.S. Food and Drug Administration (FDA) approval will be obtained for use of pyridostigmine bromide (PB), the component of Soman Nerve Agent Pretreatment Pyridostigmine (SNAPP) to counter additional nerve agents. A third component to INATS is a centrally acting medical countermeasure designed to treat the nerve agent effects on the central nervous system.
- Hemorrhagic Fever Viruses (HFV) medical countermeasures: These countermeasures will mitigate the threat of illness or death, as well as lessen issues with performance degradation resulting from exposure to hemorrhagic fever viruses (Ebola and Marburg). Due to the severity of these diseases, HFV therapeutics will be administered to infected warfighters while under direct medical observation.
- Emerging Infectious Disease Therapeutics (EID Tx): These therapeutics will provide broad-spectrum medical countermeasures to protect against naturally occurring or biologically engineered influenza viruses. This therapeutic will mitigate the threat of pandemic- and drug-resistant influenza viruses and will mitigate performance degradation issues associated with exposure to this organism.
BENEFIT TO THE WARFIGHT
Therapeutics play a critical and strategic role in chemical and biological defense by providing the warfighter with shield-and-sustain capabilities against known or novel threats.
- System attributes established in requirements documentation